Opportunities and challenges with microphysiological systems: a pharma end-user perspective

Using human-relevant, translational in vitro models is widely considered to reduce attrition during drug discovery and development. Despite this, the adoption of models based on microphysiological systems — organs-on-chips or organoids — by pharma companies is moderate at best, and realizing the full potential of these models will need greater collaboration between stakeholders. Using human-relevant, translational in vitro models is widely...